Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months
NCT01881191 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2016-02-12
Summary
This study will evaluate the effects of Aubagio on changes in the brain using MRI.
Conditions
Interventions
- OTHER
-
MRI
Sponsors & Collaborators
-
University at Buffalo
lead OTHER
Principal Investigators
-
Robert Zivadinov, MD,PhD,FAAN · University at Buffalo
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-06-30
- Primary Completion
- 2015-10-31
- Completion
- 2015-10-31
Countries
- United States
Study Locations
More Related Trials
-
To Study the Pathophysiological Features of Multiple Sclerosis
NCT04242056 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)
NCT01188811 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study
NCT00937677 ·Status: COMPLETED
-
Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis
NCT01395316 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)
NCT00239655 ·Status: TERMINATED ·Phase: PHASE2
-
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
NCT01895335 ·Status: COMPLETED ·Phase: PHASE4
-
Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis
NCT01071512 ·Status: COMPLETED ·Phase: NA
-
Cognition and MRI Markers in MS Patients With Aubagio® Treatment
NCT03768648 ·Status: COMPLETED ·Phase: NA
-
Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis
NCT03025269 ·Status: COMPLETED
-
Clinical Disease Activity With Long Term Natalizumab Treatment
NCT02677077 ·Status: COMPLETED
-
Teriflunomide Tecfidera LMCE
NCT03526224 ·Status: COMPLETED
-
An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
NCT01838668 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Evobrutinib in Participants With RMS (evolutionRMS 1)
NCT04338022 ·Status: TERMINATED ·Phase: PHASE3
-
Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis
NCT02021162 ·Status: COMPLETED
-
Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target
NCT03850301 ·Status: RECRUITING ·Phase: NA
-
Advanced MRI Sequences in Multiple Sclerosis and Its Mimics
NCT03608605 ·Status: UNKNOWN
-
An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis
NCT00751881 ·Status: COMPLETED ·Phase: PHASE3
-
Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
NCT00097331 ·Status: COMPLETED ·Phase: PHASE2
-
Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis
NCT04201470 ·Status: COMPLETED ·Phase: NA
-
Multimodal Exploration of Patients With Multiple Sclerosis for an Early Detection of Subtle Progression
NCT05941975 ·Status: RECRUITING ·Phase: NA
-
Cognitive Effects of Immunomodulatory Drugs in MS
NCT00229502 ·Status: COMPLETED
-
Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis
NCT01199640 ·Status: COMPLETED ·Phase: PHASE2
-
Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
NCT00001248 ·Status: RECRUITING
-
Comprehensive Analysis of Relapse in Multiple Sclerosis
NCT01906684 ·Status: UNKNOWN ·Phase: NA
-
Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis
NCT00134563 ·Status: COMPLETED ·Phase: PHASE3